Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Expression and co-expression of serotonin and dopamine transporters in social anxiety disorder: a multitracer positron emission tomography study

Abstract

Serotonin and dopamine are putatively involved in the etiology and treatment of anxiety disorders, but positron emission tomography (PET) studies probing the two neurotransmitters in the same individuals are lacking. The aim of this multitracer PET study was to evaluate the regional expression and co-expression of the transporter proteins for serotonin (SERT) and dopamine (DAT) in patients with social anxiety disorder (SAD). Voxel-wise binding potentials (BPND) for SERT and DAT were determined in 27 patients with SAD and 43 age- and sex-matched healthy controls, using the radioligands [11C]DASB (3-amino-4-(2-dimethylaminomethylphenylsulfanyl)-benzonitrile) and [11C]PE2I (N-(3-iodopro-2E-enyl)-2beta-carbomethoxy-3beta-(4′-methylphenyl)nortropane). Results showed that, within transmitter systems, SAD patients exhibited higher SERT binding in the nucleus accumbens while DAT availability in the amygdala, hippocampus, and putamen correlated positively with symptom severity. At a more lenient statistical threshold, SERT and DAT BPND were also higher in other striatal and limbic regions in patients, and correlated with symptom severity, whereas no brain region showed higher binding in healthy controls. Moreover, SERT/DAT co-expression was significantly higher in SAD patients in the amygdala, nucleus accumbens, caudate, putamen, and posterior ventral thalamus, while lower co-expression was noted in the dorsomedial thalamus. Follow-up logistic regression analysis confirmed that SAD diagnosis was significantly predicted by the statistical interaction between SERT and DAT availability, in the amygdala, putamen, and dorsomedial thalamus. Thus, SAD was associated with mainly increased expression and co-expression of the transporters for serotonin and dopamine in fear and reward-related brain regions. Resultant monoamine dysregulation may underlie SAD symptomatology and constitute a target for treatment.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1: Altered expression of serotonin and dopamine transporters in social anxiety disorder.
Fig. 2: Altered co-expression of serotonin and dopamine transporters in social anxiety disorder.

References

  1. 1.

    Stein MB, Stein DJ. Social anxiety disorder. Lancet 2008;371:1115–25.

    PubMed  Article  PubMed Central  Google Scholar 

  2. 2.

    Brühl AB, Delsignore A, Komossa K, Weidt S. Neuroimaging in social anxiety disorder—a meta-analytic review resulting in a new neurofunctional model. Neurosci Biobehav Rev. 2014;47:260–80.

    PubMed  Article  PubMed Central  Google Scholar 

  3. 3.

    Berger M, Gray JA, Roth BL. The expanded biology of serotonin. Annu Rev Med. 2009;60:355–66.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  4. 4.

    Gordon JA, Hen R. The serotonergic system and anxiety. Neuromolecular Med 2004;5:27–40.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  5. 5.

    Mayo-Wilson E, Dias S, Mavranezouli I, Kew KMA, Clark DM, Ades A, et al. Psychological and pharmacological interventions for social anxiety disorder in adults: a systematic review and network meta-analysis. Lancet Psychiatry 2014;1:368–76.

    PubMed  PubMed Central  Article  Google Scholar 

  6. 6.

    Lanzenberger RR, Mitterhauser M, Spindelegger C, Wadsak W, Klein N, Mien LK, et al. Reduced serotonin-1A receptor binding in social anxiety disorder. Biol Psychiatry. 2007;61:1091–89.

    Article  CAS  Google Scholar 

  7. 7.

    Frick A, Åhs F, Engman J, Jonasson M, Alaie I, Björkstrand J. et al. Serotonin synthesis and reuptake in social anxiety disorder a positron emission tomography study. JAMA Psychiatry. 2015;72:794–802.

    PubMed  Article  PubMed Central  Google Scholar 

  8. 8.

    Furmark T, Marteinsdottir I, Frick A, Heurling K, Tillfors M, Appel L, et al. Serotonin synthesis rate and the tryptophan hydroxylase-2: G-703T polymorphism in social anxiety disorder. J Psychopharmacol 2016;30:1028–35.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  9. 9.

    Frick A, Åhs F, Appel L, Jonasson M, Wahlstedt K, Bani M, et al. Reduced serotonin synthesis and regional cerebral blood flow after anxiolytic treatment of social anxiety disorder. Eur Neuropsychopharmacol 2016;26:1775–83.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  10. 10.

    van der Wee NJ, van Veen JF, Stevens H, van Vliet IM, van Rijk PP, Westenberg HG. Increased serotonin and dopamine transporter binding in psychotropic medication-naive patients with generalized social anxiety disorder shown by 123I-beta-(4-iodophenyl)-tropane SPECT. J Nucl Med. 2008;49:757–63.

    PubMed  Article  PubMed Central  Google Scholar 

  11. 11.

    Houle S, Ginovart N, Hussey D, Meyer JH, Wilson AA. Imaging the serotonin transporter with positron emission tomography: initial human studies with [11C]DAPP and [11C]DASB. Eur J Nucl Med. 2000;27:1719–22.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  12. 12.

    Lammel S, Ion DI, Roeper J, Malenka RC. Projection-specific modulation of dopamine neuron synapses by aversive and rewarding stimuli. Neuron. 2011;70:855–62.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  13. 13.

    de Jong JW, Afjei SA, Pollak Dorocic I, Peck JR, Liu C, Kim C, et al. A neural circuit mechanism for encoding aversive stimuli in the mesolimbic dopamine system. Neuron. 2019;101:133–51.

    PubMed  Article  CAS  PubMed Central  Google Scholar 

  14. 14.

    Smillie LD, Wacker J. Dopaminergic foundations of personality and individual differences. Front Hum Neurosci 2014;8:874.

    PubMed  PubMed Central  Article  Google Scholar 

  15. 15.

    Berridge KC, Kringelbach ML. Affective neuroscience of pleasure: reward in humans and animals. Psychopharmacology. 2008;199:457–80.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  16. 16.

    Wacker J, Smillie LD. Trait extraversion and dopamine function. Soc Personal Psychol Compass 2015;9:225–38.

    Article  Google Scholar 

  17. 17.

    Berridge KC, Kringelbach ML. Pleasure systems in the brain. Neuron. 2015;86:646–64.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  18. 18.

    Richey JA, Ghane M, Valdespino A, Coffman MC, Strege MV, White SW, et al. Spatiotemporal dissociation of brain activity underlying threat and reward in social anxiety disorder. Soc Cogn Affect Neurosci. 2017;12:81–94.

    Article  Google Scholar 

  19. 19.

    Doruyter A, Dupont P, Stein DJ, Lochner C, Warwick JM. Nuclear neuroimaging in social anxiety disorder: a review. J Nucl Med. 2018;59:1794–800.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  20. 20.

    Schneier FR, Liebowitz MR, Abi-dargham A, Zea-ponce Y, Lin S-H, Laruelle M. Low dopamine D 2 receptor binding potential in social phobia. Am J Psychiatry. 2000;157:457–9.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  21. 21.

    Schneier FR, Martinez D, Abi-Dargham A, Zea-Ponce Yolanda, Simpson HB, Liebowitz MR, et al. Striatal dopamine D2 receptor availability in OCD with and without comorbid social anxiety disorder: preliminary findings. Depress Anxiety. 2008;25:1–7.

    PubMed  Article  PubMed Central  Google Scholar 

  22. 22.

    Schneier FR, Abi-dargham A, Martinez D, Slifstein M, Whang DR, Liebowitz MR, et al. Dopamine transporters, D2 receptors, and dopamine release in generalized social anxiety disorder. Depress Anxiety. 2009;8:1–8.

    Google Scholar 

  23. 23.

    Plavén-Sigray P, Hedman E, Victorsson P, Matheson GJ, Forsberg A, Djurfeldt DR, et al. Extrastriatal dopamine D2-receptor availability in social anxiety disorder. Eur Neuropsychopharmacol. 2017;27:462–9.

    PubMed  Article  CAS  PubMed Central  Google Scholar 

  24. 24.

    Tiihonen J, Kuikka J, Bergström K, Lepola U, Koponen H, Leinonen E. Dopamine reuptake site densities in patients with social phobia. Am J Psychiatry. 1997;154:239–42.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  25. 25.

    Warwick JM, Carey PD, Cassimjee N, Lochner S, Hemmings H, Smook-Moolman H, et al. Dopamine transporter binding in social anxiety disorder: the effect of treatment with escitalopram. Metab Brain Dis. 2012;27:151–8.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  26. 26.

    Appel L, Jonasson M, Danfors T, Nyholm D, Askmark H, Lubberink M, et al. Use of 11C-PE2I PET in differential diagnosis of parkinsonian disorders. J Nucl Med. 2015;56:234–42.

    PubMed  Article  CAS  PubMed Central  Google Scholar 

  27. 27.

    Gray JA, McNaughton N. The neuropsychology of anxiety: an enquiry into the functions of the septo-hippocampal system. New York: Oxford University Press; 2000.

    Google Scholar 

  28. 28.

    Cloninger RC. A unified diosocial theory of personality and its role in the development of anxiety states. Psychiatr Dev. 1986;4:167–226.

    CAS  PubMed  PubMed Central  Google Scholar 

  29. 29.

    Kimbrel NA. A model of the development and maintenance of generalized social phobia. Clin Psychol Rev. 2008;28:592–612.

    PubMed  Article  PubMed Central  Google Scholar 

  30. 30.

    Corr PJ, McNaughton N. Neuroscience and approach/avoidance personality traits: A two stage (valuation-motivation) approach. Neurosci Biobehav Rev. 2012;36:2339–54.

    PubMed  Article  PubMed Central  Google Scholar 

  31. 31.

    Dewey SL, Smith GS, Logan J, Alexoff D, Ding YS, King P, et al. Serotonergic modulation of striatal dopamine measured with positron emission tomography (PET) and in viva microdialysis. J Neurosci. 1995;75:921–9.

    Google Scholar 

  32. 32.

    Smith GS, Ma Y, Dhawan V, Chaly T, Eidelberg D. Selective serotonin reuptake inhibitor (SSRI) modulation of striatal dopamine measured with [11C]-raclopride and positron emission tomography. Synapse. 2009;63:1–6.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  33. 33.

    Daws LC. Unfaithful neurotransmitter transporters: focus on serotonin uptake and implications for antidepressant efficacy. Pharm Ther. 2009;121:89–99.

    CAS  Article  Google Scholar 

  34. 34.

    Nakamura K. The role of the dorsal raphé nucleus in reward-seeking behavior. Front Integr Neurosci. 2013;7:1–18.

    Article  Google Scholar 

  35. 35.

    Esposito E, Di Matteo V, Di Giovanni G. Serotonin-dopamine interaction: an overview. Prog Brain Res. 2008;172:3–6.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  36. 36.

    Dray A, Gonye TJ, Oakley NR, Tanner T. Evidence for the existence of a raphe projection to the substantia nigra in rat. Brain Res. 1976;113:45–57.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  37. 37.

    Forstner AJ, Rambau S, Friedrich N, Ludwig KU, Böhmer AC, Mangold E, et al. Further evidence for genetic variation at the serotonin transporter gene SLC6A4 contributing toward anxiety. Psychiatr Genet. 2017;27:96–102.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  38. 38.

    Rhodes RA, Murthy NV, Dresner MA, Selvaraj S, Stavrakakis N, Babar S, et al. Human 5-HT transporter availability predicts amygdala reactivity in vivo. J Neurosci. 2007;27:9233–7.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  39. 39.

    Furmark T, Tillfors M, Garpenstrand H, Marteinsdottir I, Långström B, Oreland L, et al. Serotonin transporter polymorphism related to amygdala excitability and symptom severity in patients with social phobia. Neurosci Lett. 2004;362:189–92.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  40. 40.

    Furmark T, Henningsson S, Appel L, Åhs F, Linnman C, Pissiota A, et al. Genotype over diagnosis in amygdala responsiveness: affective processing in social anxiety disorder. J Psychiatry Neurosci. 2009;34:30–40.

    PubMed  PubMed Central  Google Scholar 

  41. 41.

    Bergman O, Åhs F, Furmark T, Appel L, Linnman C, Faria V, et al. Association between amygdala reactivity and a dopamine transporter gene polymorphism. Transl Psychiatry 2014;4:e420.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  42. 42.

    American Psychiatric Association. Diagnostic and statistical manual of mental disorders. Text Revision (DSM-IV-TR). 4th ed. Arlington: American Psychiatric Association; 2000.

  43. 43.

    Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The mini-international neuropsychiatric interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59:22–33.

    Google Scholar 

  44. 44.

    Rytwinski NK, Fresco DM, Heimberg RG, Coles ME, Liebowitz LR, Cissel S, et al. Screening for social anxiety disorder with the self-report version of the Liebowitz Social Anxiety Scale. Depress Anxiety. 2009;26:34–8.

    PubMed  Article  PubMed Central  Google Scholar 

  45. 45.

    Logan J, Fowler JS, Volkow ND, Wang G-J, Ding Y-S, Alexoff DL. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab. 1996;16:834–40.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  46. 46.

    Gunn RN, Lammertsma AA, Hume SP, Cunningham VJ. Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. Neuroimage. 1997;6:279–87.

    CAS  PubMed  Article  Google Scholar 

  47. 47.

    Jonasson M, Appel L, Engman J, Frick A, Nyholm D, Askmark H, et al. Validation of parametric methods for [11C]PE2I positron emission tomography. Neuroimage. 2013;74:172–78.

    PubMed  Article  PubMed Central  Google Scholar 

  48. 48.

    Svarer C, Madsen K, Hasselbalch SG, Pinborg LH, Haugbøl S, Frøkjær VG, et al. MR-based automatic delineation of volumes of interest in human brain PET images using probability maps. Neuroimage. 2005;24:969–79.

    PubMed  Article  PubMed Central  Google Scholar 

  49. 49.

    Frick A, Åhs F, Palmquist ÅM, Pissiota A, Wallenquist U, Fernandez M, et al. Overlapping expression of serotonin transporters and neurokinin-1 receptors in posttraumatic stress disorder: a multi-tracer PET study. Mol Psychiatry. 2016;21:1400–7.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  50. 50.

    Plavén-Sigray P, Gustavsson P, Farde L, Borg J, Stenkrona P, Nyberg L, et al. Dopamine D1 receptor availability is related to social behavior: a positron emission tomography study. Neuroimage. 2014;102:590–5.

    PubMed  Article  CAS  PubMed Central  Google Scholar 

  51. 51.

    Maldjian JA, Laurienti PJ, Kraft RA, Burdette JH. An automated method for neuroanatomic and cytoarchitectonic atlas-based interrogation of fMRI data sets. Neuroimage. 2003;19:1233–9.

    PubMed  Article  PubMed Central  Google Scholar 

  52. 52.

    Hammers A, Allom R, Koepp MJ, Free SL, Myers R, Lemieux L, et al. Three-dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe. Hum Brain Mapp. 2003;19:224–47.

    PubMed  Article  PubMed Central  Google Scholar 

  53. 53.

    Öhman A. The role of the amygdala in human fear: automatic detection of threat. Psychoneuroendocrinology. 2005;30:953–8.

    PubMed  Article  PubMed Central  Google Scholar 

  54. 54.

    Adhikari A, Lerner TN, Finkelstein J, Pak S, Jennings JH, Davidson TJ, et al. Basomedial amygdala mediates top-down control of anxiety and fear. Nature. 2015;527:179–85.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  55. 55.

    Hensler JG. Serotonergic modulation of the limbic system. Neurosci Biobehav Rev. 2006;30:203–14.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  56. 56.

    Salgado-Pineda P, Delaveau P, Blin O, Nieoullon A. Dopaminergic contribution to the regulation of emotional perception. Clin Neuropharmacol. 1979;28:228–37.

    Article  Google Scholar 

  57. 57.

    Schultz W. Reward functions of the basal ganglia. J Neural Transm. 2016;123:679–93.

    PubMed  Article  PubMed Central  Google Scholar 

  58. 58.

    Bas-Hoogendam JM, van Steenbergen H, Pannekoek NJ, Fouche JP, Lochner C, Hattingh CJ, et al. Voxel-based morphometry multi-center mega-analysis of brain structure in social anxiety disorder. NeuroImage Clin. 2017;16:678–88.

    PubMed  PubMed Central  Article  Google Scholar 

  59. 59.

    Carlezon WA, Thomas MJ. Biological substrates of reward and aversion: a nucleus accumbens activity hypothesis. Neuropharmacology. 2009;56:122–32.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  60. 60.

    Wager TD, Davidson ML, Hughes BL, Lindquist MA, Ochsner KN. Prefrontal-subcortical pathways mediating successful emotion regulation. Neuron. 2008;59:1037–50.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  61. 61.

    Cardinal RN, Parkinson JA, Hall J, Everitt BJ. Emotion and motivation: the role of the amygdala, ventral striatum, and prefrontal cortex. Neurosci Biobehav Rev. 2002;26:321–52.

    PubMed  Article  PubMed Central  Google Scholar 

  62. 62.

    Moran RJ, Kishida KT, Lohrenz T, Saez I, Laxton AW, Witcher MR, et al. The protective action encoding of serotonin transients in the human brain. Neuropsychopharmacology. 2018;43:1425–35.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  63. 63.

    Browne CJ, Abela AR, Chu D, Li Z, Ji X, Lambe EK, et al. Dorsal raphe serotonin neurons inhibit operant responding for reward via inputs to the ventral tegmental area but not the nucleus accumbens: evidence from studies combining optogenetic stimulation and serotonin reuptake inhibition. Neuropsychopharmacology. 2018;44:793–804.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  64. 64.

    Shirayama Y, Chaki S. Neurochemistry of the nucleus accumbens and its relevance to depression and antidepressant action in rodents. Curr Neuropharmacol. 2006;4:277–91.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  65. 65.

    Stuber GD, Sparta DR, Stamatakis AM, van Leeuwen WA, Hardjoprajitno JE, Cho S, et al. Excitatory transmission from the amygdala to nucleus accumbens facilitates reward seeking. Nature. 2011;475:377–80.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  66. 66.

    Oler JA, Fox AS, Shelton SE, Christian BT, Dhanabalan M, Oakes TR, et al. Serotonin transporter availability in the amygdala and bed nucleus of the stria terminalis predicts anxious temperament and brain glucose metabolic activity. J Neurosci. 2009;29:9961–6.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  67. 67.

    Takano A, Arakawa R, Hayashi M, Takahashi H, Ito H, Suhara T. Relationship between neuroticism personality trait and serotonin transporter binding. Biol Psychiatry. 2007;62:588–92.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  68. 68.

    Moriyama TS, Felicio AC, Chagas MHN, Tardelli VS, Ferraz HB, Tumas V, et al. Increased dopamine transporter density in Parkinson’s disease patients with social anxiety disorder. J Neurol Sci. 2011;310:53–7.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  69. 69.

    Fisher PM, Meltzer CC, Ziolko SK, Price JC, Hariri AR. Capacity for 5-HT1A-mediated autoregulation predicts amygdala reactivity. Nat Neurosci. 2006;9:1362–3.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  70. 70.

    Näslund J, Studer E, Pettersson R, Hagsäter M, Nilsson S, Nissbrandt H, et al. Differences in anxiety-like behaviour within a batch of Wistar rats are associated with differences in serotonergic transmission, enhanced by acute SSRI administration and abolished by serotonin depletion. Int J Neuropsychopharmacol. 2015;18:pyv018.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  71. 71.

    Sossi V, De La Fuente-Fernández R, Schulzer M, Troiano AR, Ruth TJ, Stoessl AJ. Dopamine transporter relation to dopamine turnover in Parkinson’s disease: a positron emission tomography study. Ann Neurol. 2007;62:468–74.

    PubMed  Article  PubMed Central  Google Scholar 

  72. 72.

    Zhuang X, Oosting RS, Jones SR, Gainetdinov RR, Miller GW, Caron MG, et al. Hyperactivity and impaired response habituation in hyperdopaminergic mice. Proc Natl Acad Sci. 2001;98:1982–87.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  73. 73.

    Carpenter AC, Saborido TP, Stanwood GD. Development of hyperactivity and anxiety responses in dopamine transporter-deficient mice. Dev Neurosci 2012;34:250–7.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  74. 74.

    Richey JA, Rittenberg A, Hughes L, Damiano CR, Sabatino A, Miller S, et al. Common and distinct neural features of social and non-social reward processing in autism and social anxiety disorder. Soc Cogn Affect Neurosci. 2014;9:367–77.

    PubMed  Article  PubMed Central  Google Scholar 

  75. 75.

    Farde L, Plavén-Sigray P, Borg J, Cervenka S. Brain neuroreceptor density and personality traits: towards dimensional biomarkers for psychiatric disorders. Philos Trans R Soc B Biol Sci. 2018;373:20170156.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

Supported by the Swedish Research Council and Riksbankens Jubileumsfond—the Swedish Foundation for Humanities and Social Sciences (TF). AF is supported by The Kjell and Märta Beijer Foundation. We thank Jörgen Rosén, Fredrik Åhs, Johannes Björkstrand, Thomas Ågren, Hanna Wallberg, Henrik Annerstedt, Nimo Farah, Jonas Engman, Per Carlbring, Gerhard Andersson, Margareta Reis, and Elna-Marie Larsson for their assistance.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Olof R. Hjorth.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Hjorth, O.R., Frick, A., Gingnell, M. et al. Expression and co-expression of serotonin and dopamine transporters in social anxiety disorder: a multitracer positron emission tomography study. Mol Psychiatry (2019). https://doi.org/10.1038/s41380-019-0618-7

Download citation

Further reading

Search

Quick links